Friday, November 21, 2008
De Novo Announces New Partnering Opportunity in Diabetes
CAMBRIDGE, England and SANTA ROSA, California, 9 April 2007 - De Novo Pharmaceuticals Ltd, a world leader in computational drug design, has announced that it has completed work on the in silico design of novel inhibitors for 11 beta-hydroxysteroid dehydrogenase. This work is available for partnering opportunities.
De Novo is applying SkelGen®, the Company’s proprietary in silico drug design platform, to the design of new compounds for significant targets within the diabetes field. SkelGen is a structure-based drug design technology platform that has been shown to improve the speed and effectiveness of the drug discovery process.
Philip Dean, Chief Scientific Officer at De Novo, commented: "Metabolic disease is an important therapeutic area with many targets that present a major opportunity for De Novo`s technologies. The design of many novel scaffolds for this key diabetes target extends the Company`s capabilities and is our first program in this new therapeutic area."
De Novo is applying SkelGen®, the Company’s proprietary in silico drug design platform, to the design of new compounds for significant targets within the diabetes field. SkelGen is a structure-based drug design technology platform that has been shown to improve the speed and effectiveness of the drug discovery process.
Philip Dean, Chief Scientific Officer at De Novo, commented: "Metabolic disease is an important therapeutic area with many targets that present a major opportunity for De Novo`s technologies. The design of many novel scaffolds for this key diabetes target extends the Company`s capabilities and is our first program in this new therapeutic area."
Published: 9th Apr 2007 - 12:13:17
Modified: 11th May 2007 - 13:15:36
